A 75-Second Retinal Scan for Rs 100: Pune-Based Remidio Wins Anjani Mashelkar Prize 2026
Reported by Mubarak Ansari
Pune, 17th November 2026: Remidio has won the Anjani Mashelkar Prize 2026 for its portable, non-invasive retinal imaging technology that uses artificial intelligence (AI) to screen for multiple eye and systemic health conditions.
The technology enables a retinal scan in approximately 75 seconds at a cost of around Rs 100. According to the company, the platform can screen for 10 conditions, including diabetic retinopathy, glaucoma and age-related eye degeneration, as well as diabetes, hypertension, cardiovascular disease, chronic kidney disease, anaemia, pregnancy-related risks and gestational diabetes.
Powered by offline AI, the technology can operate without an internet connection, laboratory facilities or an ophthalmologist being physically present at the screening location.
The innovation is aimed at improving access to early screening, particularly in underserved communities where access to specialist healthcare, diagnostic facilities and affordable testing remains limited.
The award was presented at the 14th National Conference on Social Innovation, organised by the Pune International Centre (PIC). The award ceremony was attended by Kiran Karnik, Chairperson of HelpAge India and former President of NASSCOM; Dr R. A. Mashelkar, Chairman of the Anjani Mashelkar Foundation and President of PIC; and Dr Vijay Kelkar, Vice President of PIC. Dr Anand Sivaraman, Founder of Remidio, received the award on behalf of the company.
Speaking on the recognition, Dr Sivaraman said, “We are truly honoured to receive the prestigious Anjani Mashelkar Prize. Dr Mashelkar’s ‘more from less for more’ has been our compass. Next, we turn the eye into a window to a person’s overall health, for everyone. India’s moment as a product nation is here.”
AI-powered screening for underserved communities
The technology is designed to enable frontline healthcare workers to conduct retinal screenings at primary health centres, vision centres, outreach camps and mobile clinics, including facilities in remote locations.
The company said its Remidio Connect platform links retinal scans with patient records, AI-generated reports, referrals and follow-up services.
This is intended to help healthcare providers identify people who may require further medical evaluation and ensure continuity of care.
Explaining the significance of the innovation, Dr R. A. Mashelkar, Founder Chairman of the Anjani Mashelkar Foundation, said, “Remidio’s game-changing portable, non-invasive platform reveals the eye’s power to detect life-threatening conditions, thus opening a realm of possibilities to make healthcare a basic human right in India and to all the excluded people of the world.”
Technology deployed in 55 countries
According to the company, Remidio’s technology has received 12 regulatory approvals, including FDA listing. Its devices have been deployed across more than 4,000 locations or units in over 55 countries, with more than 16 million patients screened worldwide.
The technology was also highlighted by Bill Gates in an April 2026 article published on Gates Notes, which discussed efforts to prevent stillbirths and the role of technology in reaching underserved maternal healthcare settings.
Commenting on the innovation, Gates said, “When we see something clever like this, it’s exactly what our biggest goal is and that is to save lives.”
